In our continuing series on role the environment plays in thoracic oncology, Dr. Roselle De Guzman outlines the risks posed by our changing climate and the potential benefits of taking a proactive approach to reduce those risks. Read more
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies. Read more
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care. Read more
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent. Read more
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients. Read more
Dr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes. Read more
Dr. Lucia Viola says that access to genomic profiling is crucial for gathering information about patients who do not smoke. Read more
Dr. Stella Martinez recently shared the latest data and explored the challenges and opportunities in lung cancer surgery in Latin America. Read more
Patient Advocates Angus Pratt and Terri Ann DiJulio explore the key role that the medical community plays in helping patients and families understand the importance of palliative care. Read more
Durvalumab is recommended for approval in the EU, Health Canada approves pembrolizumab, and the US FDA grants priority review to datopotamab deruxtecan. Read more